Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.63 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580142 | 0.89 | FAAH (0.59) | FAAHTSHRKDM4ELMNADRD2 | |
| SCHEMBL4579632 | 0.85 | HDAC1 (0.72) | HDAC1HDAC2HDAC3 | |
| SCHEMBL8223506 | 0.85 | KDM4E (0.53) | HDAC1HDAC2HDAC3FAAHTSHR | |
| SCHEMBL4580468 | 0.80 | HDAC1 (0.52) | HDAC1HDAC2HDAC3LMNADRD2 | |
| SCHEMBL4579926 | 0.80 | HDAC1 (0.52) | HDAC1HDAC2HDAC3LMNADRD2 | |
| SCHEMBL4579931 | 0.80 | HDAC1 (0.52) | HDAC1HDAC2HDAC3LMNADRD2 | |
| SCHEMBL4579936 | 0.80 | HDAC1 (0.52) | HDAC1HDAC2HDAC3LMNADRD2 | |
| SCHEMBL4755005 | 0.80 | KDM4E (0.54) | HDAC1HDAC2KDM4ELMNADRD2 | |
| SCHEMBL4578391 | 0.80 | DRD2 (0.56) | HDAC1HDAC2HDAC3DRD2DRD4 | |
| SCHEMBL8228556 | 0.80 | HDAC1 (0.52) | HDAC1HDAC2HDAC3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC2 5/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.